Quantitative Assessment of PALB2 and BRIP1 Genes Expression in the Breast Cancer Cell Line under the Influence of Tamoxifen

PALB2 and BRIP1 Genes Expression under Tamoxifen

Authors

  • Hamed Kharrati-Koopaee Institute of biotechnology, Shiraz University, Shiraz, Iran
  • Seyed Taghi Heydari Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mehdi Dianatpour Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Kamran Bagheri Lankarani Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Shiraz, Iran

DOI:

https://doi.org/10.31661/gmj.v12i.2483

Abstract

Background:Breast cancer is considered one of the leading causes of mortality in the world. Cancer incidence and consequently, drug consumption can strongly influence gene expressions at the transcriptome level. Therefore, the assessment of the candidate biomarkers’ gene expression can accelerate the diagnosis process and increase the chance of treatment and remission. In this regard, the quantitative assessment of Partner and localizer of BRCA2 (PALB2) and BRCA1 Interacting Helicase 1 (BRIP1) genes expression in the breast cancer cell line under the treatment of Tamoxifen (TAM) was executed in this study. Materials and Methods :MCF7 cells were cultured as TAM-treated and control groups. RNA extraction and cDNA synthesis were performed based on the instructions of provided kits. qPCR Hi-ROX Master Mix kit was applied to the Quantitative Real-Time Polymerase Chain Reaction (Q-PCR). The outputs of Q-PCR were analyzed by REST statistical software. Results:Outcomes derived from data analysis of BRIP1 gene expression did not show any significant difference between the gene expression of control and TAM-treated groups. The expression of PALB2 was significantly higher in the TAM-treated group compared to the control group (P<0.05). Conclusion:Our findings showed a significant alteration between PALB2 gene expression in the TAM-treated breast cancer cell line and the control cell line. The quantitative assessment of mentioned genes as possible markers could be considered a non-invasive method for breast cancer in the processes of prognostic evaluations, screening, and treatment monitoring.

References

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7): e48-e72

https://doi.org/10.5858/134.7.e48

PMid:20586616

Mohammadpour A, Jahangirian E, Moharrami T, Goljah Rad G, Javanparast Sheikhani L, Taghizadeh S. Breast Cancer, Genetic Factors and Methods of Diagnosis. Sarem J Reprod Med. 2020;4(4):198-207.

https://doi.org/10.52547/sjrm.4.4.198

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020.

https://doi.org/10.1016/j.intimp.2020.106535

PMid:32361569

Klinge C. Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication. Non-Coding RNA. 2018;4(4):40.

https://doi.org/10.3390/ncrna4040040

PMid:30545127 PMCid:PMC6316884

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clinic Oncol. 2014;32(21):2255.

https://doi.org/10.1200/JCO.2013.54.2258

PMid:24868023 PMCid:PMC4876310

Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205.

https://doi.org/10.1038/nrd1031

PMid:12612646

Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643-58.

https://doi.org/10.1677/erc.1.00776

PMid:15613444

Piggott L, da Silva AM, Robinson T, Santiago-Gómez A, Simões BM, Becker M, et al. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP. Clin Cancer Res. 2018: 1381.2017.

https://doi.org/10.1158/1078-0432.CCR-17-1381

PMid:29363524

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer I. 2004;96(12):926-35.

https://doi.org/10.1093/jnci/djh166

PMid:15199112

Li X, Rouchka EC, Brock GN, Yan J, O'Toole TE, Tieri DA, et al. A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes. PloS one. 2018;13(8): e0201813.

https://doi.org/10.1371/journal.pone.0201813

PMid:30089167 PMCid:PMC6082555

Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255-66.

https://doi.org/10.1016/j.molonc.2010.04.001

PMid:20434415 PMCid:PMC2904860

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E. Breast-cancer risk in families with mutations in PALB2. New Engl J Med. 2014;371(6):497-506.

https://doi.org/10.1056/NEJMoa1400382

PMid:25099575 PMCid:PMC4157599

Amirhamzeh SA, Esfahani K, Salahshourifar I, Moslemi E. Evaluation of PALB2 Gene Expression in Breast Cancer. Journal of Sciences, Islamic Republic of Iran. 2020.

Shafiee E, Hesampour A. Quantitative study of PALB2 and BRIP1 gene expression in the population of Iranian women with Breast cancer compared to controls. Medic Sci J Islamic Azad Uni. 2019. 28(4):283-289.

https://doi.org/10.29252/iau.28.4.283

Kharrati-Koopaee H, Ebrahimie E, Dadpasand M, Niazi A, Esmailizadeh A. Genomic analysis reveals variant association with high altitude adaptation in native chickens. Sci Rep. 2019 Jun 25;9(1):9224

https://doi.org/10.1038/s41598-019-45661-7

PMid:31239472 PMCid:PMC6592930

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402-8.

https://doi.org/10.1006/meth.2001.1262

PMid:11846609

Li N, Zethoven M, McInerny S, et alContribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testingJournal of Medical Genetics Published Online First: .2022.

https://doi.org/10.1136/jmedgenet-2021-108399

PMid:35396271

Dorling L, Carvalho S, Allen J, González-Neira A. et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021. 4;384(5):428-439.

Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y. Molecular mechanisms of PALB2 function and its role in breast cancer management. Fron Oncol. 2020. 28;10:301.

https://doi.org/10.3389/fonc.2020.00301

PMid:32185139 PMCid:PMC7059202

Mistry DA, French PW. Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl). 2016; 10:191-196.

https://doi.org/10.4137/BCBCR.S40693

PMid:27867299 PMCid:PMC5110222

Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016; 34:1455-59.

https://doi.org/10.1200/JCO.2015.63.7454

PMid:26786923

Huber-Keener KJ, Liu X, Wang Z, Wang Y, Freeman W, Wu S, Planas-Silva MD, Ren X, Cheng Y, Zhang Y, Vrana K, Liu CG, Yang JM, Wu R. Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data. PLoS One. 2012;7(7):e41333.

https://doi.org/10.1371/journal.pone.0041333

PMid:22844461 PMCid:PMC3402532

Men X, Ma J, Wu T, Pu J, Wen S, Shen J, Wang X, Wang Y, Chen C, Dai P. Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer. Oncotarget. 2017. 26;9(3):4074-4089.

https://doi.org/10.18632/oncotarget.23694

PMid:29423105 PMCid:PMC5790522

Xu E, Guan T, Hu M, Tong D, Ge R, Liu Y. Establishment and transcriptome characterization of tamoxifen-resistant canine mammary gland tumor cells. Research in Veterinary Science. 2022. 1;145:135-46.

https://doi.org/10.1016/j.rvsc.2022.02.018

PMid:35193047

. Li Z, Yu D, Li H, Lv Y, Li S. Long noncoding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. International journal of oncology. 2019. 1;54(3):1033-42.

https://doi.org/10.3892/ijo.2019.4679

Gupta I, Ouhtit A, Al-Ajmi A, Rizvi SG, Al-Riyami H, Al-Riyami M, Tamimi Y. BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes. Endocrine connections. 2018. 1;7(1):65-77.

https://doi.org/10.1530/EC-17-0173

PMid:29138235 PMCid:PMC5744628

Downloads

Published

2023-12-26

How to Cite

Kharrati-Koopaee, H., Heydari, S. T., Dianatpour, M., & Bagheri Lankarani, K. (2023). Quantitative Assessment of PALB2 and BRIP1 Genes Expression in the Breast Cancer Cell Line under the Influence of Tamoxifen: PALB2 and BRIP1 Genes Expression under Tamoxifen. Galen Medical Journal, 12, e2483. https://doi.org/10.31661/gmj.v12i.2483

Issue

Vol. 12 (2023): 2023

Section

Original Article

License

Copyright (c) 2023 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0/